Profund Advisors LLC Acquires 6,814 Shares of AstraZeneca PLC $AZN

Profund Advisors LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 14.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,952 shares of the company’s stock after acquiring an additional 6,814 shares during the quarter. Profund Advisors LLC’s holdings in AstraZeneca were worth $3,700,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Lindbrook Capital LLC grew its position in shares of AstraZeneca by 1.9% in the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock worth $557,000 after buying an additional 141 shares during the last quarter. Sage Mountain Advisors LLC grew its stake in AstraZeneca by 3.4% during the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock worth $329,000 after buying an additional 147 shares during the last quarter. Pekin Hardy Strauss Inc. increased its position in AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock valued at $255,000 after buying an additional 148 shares in the last quarter. Richardson Financial Services Inc. raised its stake in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its holdings in AstraZeneca by 0.7% in the first quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock worth $1,743,000 after acquiring an additional 155 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating for the company. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Performance

NASDAQ AZN opened at $84.58 on Monday. The stock has a market capitalization of $262.32 billion, a price-to-earnings ratio of 31.80, a PEG ratio of 1.52 and a beta of 0.34. The stock has a 50-day moving average of $81.41 and a 200 day moving average of $75.60. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $86.57.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.08 earnings per share. Sell-side analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.